<pmc-articleset xmlns:ns0="http://www.w3.org/1999/xlink">
<article xml:lang="en" article-type="research-article" dtd-version="1.4">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hematology Am Soc Hematol Educ Program</journal-id>
<journal-id journal-id-type="iso-abbrev">Hematology Am Soc Hematol Educ Program</journal-id>
<journal-id journal-id-type="pmc-domain-id">3527</journal-id>
<journal-id journal-id-type="pmc-domain">hashep</journal-id>
<journal-id journal-id-type="publisher-id">HEM</journal-id>
<journal-title-group>
<journal-title>Hematology: the American Society of Hematology Education Program</journal-title>
</journal-title-group>
<issn pub-type="ppub">1520-4391</issn>
<issn pub-type="epub">1520-4383</issn>
<publisher>
<publisher-name>The American Society of Hematology</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmcid">PMC9820434</article-id>
<article-id pub-id-type="pmcid-ver">PMC9820434.1</article-id>
<article-id pub-id-type="pmcaid">9820434</article-id>
<article-id pub-id-type="pmcaiid">9820434</article-id>
<article-id pub-id-type="pmid">36485122</article-id>
<article-id pub-id-type="doi">10.1182/hematology.2022000399</article-id>
<article-id pub-id-type="publisher-id">2022000399</article-id>
<article-version article-version-type="pmc-version">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Long-Term Effects Monitoring for Survivors of Pediatric Hematologic Malignancies</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Germline risk factors for second malignant neoplasms after treatment for pediatric hematologic malignancies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name name-style="western">
<surname>Bhatia</surname>
<given-names initials="S">Smita</given-names>
</name>
<xref rid="cor1" ref-type="corresp" />
<aff>Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1">
<bold>Correspondence</bold> Smita Bhatia, Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, 1600 7th Ave S, Lowder 500, Birmingham, AL 35233; e-mail: <email>smitabhatia@uabmc.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub" iso-8601-date="2022-12-09">
<day>09</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="ppub" iso-8601-date="2022-12-09">
<day>09</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>2022</volume>
<issue>1</issue>
<issue-id pub-id-type="pmc-issue-id">425604</issue-id>
<fpage>245</fpage>
<lpage>250</lpage>
<page-range>245-250</page-range>
<pub-history>
<event event-type="pmc-release">
<date>
<day>09</day>
<month>12</month>
<year>2022</year>
</date>
</event>
<event event-type="pmc-live">
<date>
<day>09</day>
<month>01</month>
<year>2023</year>
</date>
</event>
<event event-type="pmc-last-change">
<date iso-8601-date="2025-06-19 21:25:17.843">
<day>19</day>
<month>06</month>
<year>2025</year>
</date>
</event>
</pub-history>
<permissions>
<copyright-statement>Copyright Â© 2022 by The American Society of Hematology</copyright-statement>
<copyright-year>2022</copyright-year>
</permissions>
<self-uri content-type="pmc-pdf" ns0:href="hem.2022000399.pdf" />
<self-uri ns0:href="hem.2022000399.pdf" />
<abstract abstract-type="graphical">
<title>Visual Abstract</title>
<p>
<fig position="float" id="hem2022000399s1" orientation="portrait">
<graphic position="float" orientation="portrait" ns0:href="hem.2022000399_s1.jpg" />
</fig>
</p>
</abstract>
<abstract>
<title>Abstract</title>
<p>Survivors of childhood hematologic malignancies are at a substantially higher risk of developing subsequent neoplasms (SNs) when compared with the general population. SNs commonly observed in this population include basal cell carcinoma, brain tumors, thyroid cancer, breast cancer, bone tumors, and sarcoma. Radiation is the primary therapeutic exposure associated with the development of these SNs. There is emerging evidence of an association between chemotherapeutic exposures (alkylating agents/anthracyclines) and the development of SNs. Despite a strong dose-dependent association between therapeutic exposures and SN risk, there is significant interindividual variability in the risk for SNs for any given dose of therapeutic exposure. This interindividual variability in risk suggests the role of genetic susceptibility. This article describes the clinical and molecular epidemiology of SNs commonly observed in survivors of childhood hematologic malignancies and also highlights some of the work focusing on the development of risk prediction models to facilitate targeted interventions.</p>
</abstract>
<counts>
<page-count count="6" />
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>pmc-status-qastatus</meta-name>
<meta-value>0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-status-live</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-status-embargo</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-status-released</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-open-access</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-olf</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-manuscript</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-legally-suppressed</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-has-pdf</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-has-supplement</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-pdf-only</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-suppress-copyright</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-is-real-version</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-is-scanned-article</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-preprint</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-in-epmc</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>